Dean Hakanson
Keine laufenden Positionen mehr
Karriereverlauf von Dean Hakanson
Ehemalige bekannte Positionen von Dean Hakanson
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| OTONOMY | Technik-/Wissenschafts-/F&E-Leiter | 01.04.2015 | 31.01.2018 |
| NOVARTIS AG | Corporate Officer/Principal | 01.07.2009 | 01.05.2010 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01.01.2008 | 01.07.2009 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01.06.2005 | 01.01.2008 |
| GSK PLC | Technik-/Wissenschafts-/F&E-Leiter | 01.01.1998 | 01.01.2005 |
| National Accounts, Inc. | Corporate Officer/Principal | 01.01.1998 | 01.01.2005 |
Ausbildung von Dean Hakanson
| University of Denver | Undergraduate Degree |
| The University of Colorado School of Medicine | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 7 |
| Vereinigtes Königreich | 2 |
| Schweiz | 2 |
Operativ
| Corporate Officer/Principal | 4 |
| Chief Tech/Sci/R&D Officer | 2 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 6 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| GSK PLC | Health Technology |
| NOVARTIS AG | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Otonomy, Inc.
 Otonomy, Inc. BiotechnologyHealth Technology Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm’s product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA. | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
| National Accounts, Inc. |
- Börse
- Insiders
- Dean Hakanson
- Erfahrung
